This activity is hosted on the site of our educational partner

You will be connecting to our educational partner, which controls its own content, practices, and other policies.

You will be connecting to our educational partner, which controls its own content, practices, and other policies.

  • Overview
  • Pre-Assessment
  • Activity
  • Post-Test
  • Evaluation
  • Claim Credit
Questions about our CME?
Questions about our CME?
Hang on a second…

This CME Activity has expired and is no longer available for credit.

Looking at the Big Picture in Psoriasis: Incorporating Comorbidities and Quality of Life in Treatment Decisions

Looking at the Big Picture in Psoriasis: Incorporating Comorbidities and Quality of Life in Treatment Decisions


Slide Lecture Series

Time to Complete

1 hour


February 22, 2016


February 22, 2017
Add to Queue

Maximum Credits

1.00 / AMA PRA Category 1 Credit(s)TM
1.00 / AAPA Category 1 CME Credit

Accredited Provider

Provided by Creative Educational Concepts, Inc. (CEC) and American Academy of Physician Assistants (AAPA)

Commercial Supporter

This activity is supported by an educational grant from Lilly USA, LLC. For further information concerning Lilly grant funding, visit

Program Description

Psoriasis has a profound impact on patients’ well-being and is often linked to various psychiatric comorbidities, including depression, anxiety, and suicidality.1 Adding to this impact is the increased prevalence of comorbidities such as obesity, hypertension, dyslipidemia, diabetes, nonalcoholic fatty liver disease, smoking, and metabolic syndrome when compared to the general population.2-6 Fortunately, many treatment options exist for patients with psoriasis, with more options in development utilizing novel pathways. New findings continue to emerge that affect the way that we view the disease process, the risk of serious complications, and the possibilities for new drug development. As the understanding and treatment of psoriasis has changed significantly in recent years, it is critical that clinicians who manage this disease have a thorough understanding of the disease and treatment options.

The goal of this educational activity is to provide Physician Assistants (PAs) and other healthcare professionals who treat psoriasis patients with an understanding of the inflammatory targets for current and emerging biologic agents, the impact of complicating comorbidities, and the importance of patient quality of life in treatment decisions. This activity will give participants the ability to not only increase the number of psoriasis patients who achieve treatment goals but also to improve their overall health and quality of life.

1. Kurd SK, et al. Arch Dermatol. 2010.
2. Neimann AL, et al. J Am Acad Dermatol. 2006.
3. Cohen AD, et al. Dermatology. 2008.
4. Gisondi P, et al. Am J Cardiol. 2010.
5. Gisondi P, et al. J Hepatol. 2009.
6. Prey S, et al. J Eur Acad Dermatol Venereol. 2010.

Intended Audience

Physician assistants (PAs) and other applicable clinicians who treat patients with psoriasis

Educational Objectives

Upon completion of this activity, participants will be able to:

  • Explore the unique aspects of emerging biologic agents for psoriasis in terms of inflammatory targets, efficacy, safety, and adverse effects
  • Appraise the impact of psoriatic disease on patient quality of life, work productivity, and associated psychosocial effects
  • Examine comorbid medical conditions associated with psoriasis and identify opportunities to tailor treatment based on individual patient characteristics
  • Recognizing the importance of patient quality of life and the impact on treatment decisions, use real-world, case-based scenarios to design individualized treatment plans for patients with psoriasis that address individual patient needs such as disease severity, treatment history, quality of life, and comorbidities

Conflict Of Interest Disclosure Policy

In accordance with the Food and Drug Administration, the speakers have disclosed that there is the potential for discussions concerning off-label uses of a commercial product/device during this educational activity.

Any person who may contribute to the content of this continuing education activity must disclose significant relationships (and any known relationships of their spouse/partner) with commercial companies whose products or services are discussed in educational presentations.

Significant relationships include receiving from a commercial company research grants, consultant fees, travel, other benefits, or having a self-managed equity interest in a company.

Disclosure of a relationship is not intended to suggest or condone any bias in any presentation but is made to provide participants with information that might be of potential importance to their evaluation of a presentation.


Abby A. Jacobson, MS, PA-C
Dermatology Physician Assistant
Family Dermatology of Reading
Reading, PA
Assistant Professor
Salus University
Elkins Park, PA

Ms. Jacobson has disclosed that she is a consultant for Amgen, Celgene, Lilly, and Novartis.

Craig Leonardi, MD
Clinical Professor of Dermatology
Saint Louis University
St. Louis, MO

Dr. Leonardi has disclosed that he is a consultant for AbbVie, Amgen, Boehringer Ingelheim, Dermira, Janssen, Lilly, Leo, Pfizer, Sandoz, UCB, and Vitae; he is an investigator for Actavis, AbbVie, Amgen, Celgene, Coherus, Dermira, Galderma, Janssen, Leo, Lilly, Merck, Novartis, Pfizer, Sandoz, Stiefel, and Wyeth. He is also a member of the speakers’ bureaus for AbbVie, Celgene and Novartis.

Accredited Provider Disclosure

Laura K. Stinson, PharmD, has no financial relationships to disclose in relation to the content of this activity.




AMA PRA Category 1 Credit(s)TM

Accreditation Statement

Creative Educational Concepts, Inc. (CEC) is accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.

Designation Statement

CEC designates this online educational activity for a maximum of 1.00 AMA PRA Category 1 Credit(s)TM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.




AAPA Category I CME credit

Accreditation Statement

This program was planned in accordance with the AAPA's CME Standards for Enduring Material Programs and for Commercial Support of Enduring Material Programs.

Designation Statement

This program has been reviewed and is approved for a maximum of 1.00 hours of AAPA Category I CME credit by the Physician Assistant Review Panel. Physician Assistants should claim only those hours actually spent participating in the CME activity. This program was planned in accordance with AAPA’s CME Stan¬dards for Live Programs and for Commercial Support of Live Programs.

Disclosure of Unlabeled Use

This activity may include discussions of products or devices that are not currently approved for use by the Food and Drug Administration (FDA), or are currently investigational.


It is the policy of CEC to ensure independence, balance, objectivity, scientific rigor, and integrity in their continuing education activities.

Those involved in the development of this continuing education activity have made all reasonable efforts to ensure that information contained herein is accurate in accordance with the latest available scientific knowledge at the time of accreditation of this continuing education activity. Information regarding drugs (e.g., their administration, dosages, contraindications, adverse reactions, interactions, special warnings, and precautions) and drug delivery systems is subject to change, however, and the reader is advised to check the manufacturer's package insert for information concerning recommended dosage and potential problems or cautions prior to dispensing or administering the drug or using the drug delivery systems.

Fair balance is achieved through ongoing and thorough review of all presentation materials produced by faculty, and all educational and advertising materials produced by supporting organizations, prior to educational offerings. Approval of credit for this continuing education activity does not imply endorsement by CEC for any product or manufacturer identified.


To obtain credit, a score of 70% or better on the post-test is required. This activity is offered at no cost to participants. Please proceed with the activity until you have successfully completed this program, answered all test questions, completed the post-test and evaluation, and have received a digital copy of your credit certificate. Your online certificate will be saved on myCME within your Profile/CME History, which you can access at any time.

If you have any questions relating to the accreditation of this activity, please contact Creative Educational Concepts at (866) 360-1717.

If you have any other questions relating to your certificate or other issues with this activity, please contact

Privacy Policy


Hardware and Software Requirements
  • A computer with an internet connection
  • Internet Browser: Internet Explorer 7.x or higher, Firefox 4.x or higher, Safari 2.x or higher, or any other W3C standards compliant browser
  • Additional Software: Adobe Flash Player and/or an HTML 5 capable browser maybe required for video or audio playback. PowerPoint or Adobe Acrobat Reader may occasionally be required
Add to Queue